Skip to Content

'
Gheath Alatrash

Present Title & Affiliation

Primary Appointment

Assistant Professor, Tenure-track Physician-Scientist, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002 University of North Texas Health Science Center, Fort Worth, TX, DO, Highest Honors, Medicine
2002 University of North Texas Health Science Center, Fort Worth, TX, PHD, Biomedical Sciences - Immunology
1995 Abilene Christian University, Abilene, TX, BS, Magna Cum Laude, Biology

Postgraduate Training

7/2005-6/2008 Clinical Fellowship, Medical Oncology/Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
9/2002-6/2005 Clinical Residency, Internal Medicine/Clinician-Scholar Pathway, The Cleveland Clinic Foundation, Cleveland, OH

Board Certifications

2009 Hematology
2008 Medical Oncology
2005 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, The University of Texas Health Science Center, Graduate School of Biomedical Sciences, Houston, TX, 10/2013-present
Instructor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2009
Clinical Specialist, Intensive Care Unit, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005-2009

Honors and Awards

2008-2009 Barbara Rattay Foundation Advanced Scholar Fellow, The University of Texas MD Anderson Cancer Center
2008 Basic-Science Research Achievement, The University of Texas MD Anderson Cancer Center
2007-2008 Chief Fellow, Medical Oncology/Hematology, The University of Texas MD Anderson Cancer Center
2005 Outstanding Graduating Resident, The Cleveland Clinic Foundation
2002 Chancellor's Award for Academic Excellence and Scholarly Achievement, University of North Texas Health Science Center
2002 Dean's List for Academic Excellence (Top 5% of medical class), University of North Texas Health Science Center
2002 Who's Who Among Students in American Universities and Colleges
2001 Community Hospital Foundation G. W. Tompson Scholarship, University of North Texas Health Science Center
2001 Graduate Faculty Award for Outstanding Graduate, University of North Texas Health Science Center
2000-2001 Outstanding Graduate Student, Department of Molecular Biology and Immunology, University of North Texas Health Science Center
2000 Abbott Laboratories Research Achievement Awards, University of North Texas Health Science Center
1999 Abbott Laboratories Research Achievement Awards, University of North Texas Health Science Center
1998-1999 Medical Scientist Training Pathway Grant, University of North Texas Health Science Center
1996-2002 Psi Sigma Alpha National Honor Society, University of North Texas Health Science Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Hunsucker SA, McGary CS, Vincent BG, Enyenihi AA, Waugh JP, McKinnon KP, Bixby LM, Ropp PA, Coghill JM, Wood WA, Gabriel DA, Sarantopoulos S, Shea TC, Serody JS, Alatrash G, Rodriguez-Cruz T, Lizée G, Buntzman AS, Frelinger JA, Glish GL, Armistead PM. Peptide/MHC tetramer based sorting of CD8+ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire. Cancer Immunol Res 3(3):228-35, 3/2015. e-Pub 1/2015. PMCID: PMC4351150.
2. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 20(12):1975-81, 12/2014. e-Pub 9/2014. PMID: 25263628.
3. Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing Chimerism after Allogeneic Stem Cell Transplantation Is Associated with Longer Survival Time. Biol Blood Marrow Transplant 20(8):1139-44, 8/2014. e-Pub 4/13/2014. PMCID: PMC4099297.
4. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res 2(4):361-70, 4/2014. PMCID: PMC4000553.
5. Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. A Novel HLA-A*0201 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target in Acute Myeloid Leukemia. Clin Cancer Res 19(1):247-57, 1/2013. PMCID: PMC3537920.
6. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad Cross-Presentation of the Hematopoietically-Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. J Immunol (Journal Cover) 189(11):5476-84, 12/2012. PMCID: PMC3504175.
7. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 12/2012. PMID: 22796535.
8. Mittendorf EA, Alatrash G*(co-first author), Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anti-cancer adaptive immune response. Cancer Res 72(13):3153-62, 7/2012. PMCID: PMC3397251.
9. Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1. J Immunother 35(4):309-20, 5/2012. PMCID: PMC3326226.
10. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 12/2011. PMID: 21684343.
11. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 17(10):1490-6, 10/2011. PMID: 21338705.
12. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 9/2011. PMCID: PMC3176952.
13. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ. An Anti-PR1/HLA-A2 T Cell Receptor-Like Antibody Mediates Complement Dependent Cytotoxicity Against Acute Myeloid Leukemia Progenitor Cells. Blood 117(16):4262-72, 4/2011. PMCID: PMC3087478.
14. Armistead PM, Liang S, Li H, Lu S, Van Bergen CA, Alatrash G, St John L, Hunsucker SA, Sarantopoulos S, Falkenburg JH, Molldrem JJ. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One 6(8):e23217, 2011. PMCID: PMC3153501.
15. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 12/2010. PMCID: PMC3365857.
16. Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J. Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol 150(6):716-9, 9/2010. PMID: 20560965.
17. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2/2010. PMID: 19895616.
18. Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ. PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal. PLoS One 5(7):e11770, 2010. PMCID: PMC2909896.
19. Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis following the ingestion of 'Foxy'. Mayo Clin Proc 81(4):550-1, 4/2006. PMID: 16610577.
20. Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM. Clinical and immunologic effects of subcutaneously administered IL-12 and IFN-a2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22(14):2891-900, 7/2004. PMID: 15254058.
21. Datta A, Kitson RP, Xue Y, al-Atrash G, Mazar AP, Jones TR, Goldfarb RH. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases. In Vivo 16(6):451-7, Nov-Dec, 11/2002. PMID: 12494889.
22. Alatrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH. IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochem Biophys Res Commun 292(1):184-9, 3/2002. PMID: 11890690.
23. Alatrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH. uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Res 21(3B):1697-704, 5/2001. PMID: 11497249.
24. Alatrash G, Kitson RP, Xue Y, Goldfarb RH. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion. In Vivo 14(5):565-70, 9/2000. PMID: 11125540.
25. Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. In Vivo 14(1):101-4, Jan-Feb, 1/2000. PMID: 10757065.

Invited Articles

1. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology 3(3):e28325, 1/1/2014. e-Pub 4/8/2014. PMCID: PMC4022604.
2. Garber HR, Mirza A, Mittendorf EA, Alatrash G. Adoptive T-cell Therapy for Leukemia. Mol Cell Ther 2(25):25, 2014. e-Pub 8/2014. PMCID: PMC4452065.
3. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 12(5):631-45, 9/2013. PMID: 23668362.
4. Chawla A, Alatrash G, Wu Y, Mittendorf EA. Immune aspects of the breast tumor microenvironment. Breast Cancer Manag 2(3):231-244, 5/2013. PMCID: PMC3917569.
5. Alatrash G. Targeting cathepsin G in myeloid leukemia. Oncoimmunology 2(4):e23442, 4/2013. PMCID: PMC3654578.
6. Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev Vaccines 10(6):755-74, 6/2011. PMID: 21692698.
7. Alatrash G, Molldrem JJ. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol 4(1):37-50, 2/2011. PMCID: PMC3098525.
8. Molldrem JJ, Alatrash G. Immune rage against MAGE unleashed. Blood 116(11):1824-5, 9/2010. PMCID: PMC3173983.
9. Alatrash G, Molldrem JJ. Immunotherapy of AML. Cancer Treat Res 145:237-55, 2010. PMID: 20306255.
Other Articles
1. Alatrash G, Wierda W. Multiple Articles Covering ASH Annual Meeting 2006. ASH Daily News, 2006.
2. Alatrash G, Kim ES. Treatment of advanced non-small-cell lung cancer: First-line therapy and future directions. Oncology Special Edition 9:35-40, 2006.
3. Wierda W, Schlette E, Alatrash G. Initial treatment of chronic lymphocytic leukemia: A case report. Biological Therapy of Lymphoma 8(4):6-9, 12/2005.

Abstracts

1. Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, Quintanilla K, Armistead P, He H, Rodriguez-Cruz T, Clise-Dwyer K, Wieder E, Lizee G, Lu S, Molldrem J. Peripheral Tolerance to PR1 Is Maintained After Uptake of Soluble Proteinas-3 and Neutrophil Elastase. ASH annual meeting. Blood 116(21) (#4301), 12/2010.
2. Yang T, Alatrash G, Clise-Dwyer K, Quintanilla K, Lu S, Molldrem J. Proteinase 3 Mediates Enzyme-Independent Reversible Inhibition of CD4 and CD8 T Cell Proliferation by Blocking G1-S Transition. ASH annual meeting. Blood 116(21) (#2099), 12/2010.
3. Alatrash G, Mittendorf E, Sergeeva A, Sukhumalchandra P, Qiao N, Quintanilla K, Zhang M, Lu S, Clise-Dwyer K, Molldrem J. Soluble Inflammatory Mediators Proteinase-3 and Neutrophil Elastase Are Targeted by PR1-Specific Immunotherapy After Cellular Uptake and Cross Presentation of PR1 Peptide by Breast Cancer Cells. ASH annual meeting. Blood 116(21) (#2089), 12/2010.
4. Chiattone A, Saliba R, Andersson B, Giralt S, Sharma M, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Alatrash G, Bashir Q, Chen U, Yuen C, Chiattone, V, Champlin R, De Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). ASH annual meeting. Blood 116(21) (#3455), 12/2010.
5. Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash M, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin R, de Lima M. Allogenieic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS using myeloablative, reduced toxicity IV Busulfan/Fludarabine (BuFlu) conditioning regimen. American Society of Blood and Marrow Transplantation (ASBMT) annual meeting. Biology of Blood and Marrow Transplantation 15(2):106 (#293), 2009.
6. Alatrash G, Pelosini M, Saliba R, Rondon G, Weiqing Z, Giralt S, Kebriaaei P, Alousi A, Khouri I, Champlin R, de Lima M. Post-hematopoietic stem cell transplantation (HSCT) outcomes in patients with AML transplanted prior to achieving platelet recovery. ASBMT annual meeting. Biology of Blood and Marrow Transplantation 15(2):58 (#154), 2009.
7. Sergeeva A, Lu S, Wygant JN, Alatrash G, Quintanilla K, Molldrem JJ. Direct visualization of PR1/HLA-A2 on the membrane of HLA-A2+CD13+CD33+ myeloid leukemia blasts by a novel monoclonal antibody. ASH annual meeting. Blood 112(11):884 (#2545), 11/2008.
8. Alatrash G, Andersson BS, Pelosini M, Rondon G, Qazilbash MH, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W Saliba R, Champlin RE, De Lima M. Myeloablative, reduced toxicity IV Busulfan/Fludarabine (BuFlu) and allogeneic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS. ASH annual meeting. Blood 112(11):1031 (#2999), 11/2008.
9. Alatrash G, Pelosini M, Saliba RM, Rondon G, Zhang W, Giralt S, Kebriaei P, Alousi A, Khouri IF, Champlin RE, De Lima M. Platelet recovery prior to stem cell transplantation predicts for post-transplant outcomes in patients with AML. ASH annual meeting. Blood 112(11):1031 (#3000), 11/2008.
10. Alatrash G, Vence L, Woodward W, Ueno N, Molldrem JJ. Leukemia-associated primary granule proteins (PGPs) elastase-2 and proteinase-3 are aberrantly expressed in solid tumors: a potential therapeutic target for PR1-directed immunotherapy. ASH annual meeting. Blood 112(11) (#5440), 2008.
11. Alatrash G, Ono Y, Lu S, Sergeeva A, Sukhumalchandra P, Wang C, Wieder E, Molldrem JJ. Mistrafficking of primary granule proteins (PGPs) in leukemia simultaneously promotes PGP cross-priming and increases susceptibility to CTL killing. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (AACR) 68 (#1034), 2008.
12. Alatrash G, Ono Y, Lu S, Sergeeva A, Wang C, Wieder E, Molldrem JJ. Aberrant subcellular localization of azurophil granule proteins in myeloid leukemia favors peptide antigen presentation on MHC-I and susceptibility to killing by cytotoxic T lymphocytes. ASH annual meeting. Blood 110(11) (#4900), 2007.
13. Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Molldrem JJ. T-cell autoimmunity may contribute to neutropenia in a patient with cyclic neutropenia (CN) and double De-nova mutations in Gfi-1. ASH annual meeting. Blood 110(11) (#3298), 2007.
14. Alatrash G, Keating MJ, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Kantarjian HM, Lerner S, Wierda WG. Circulating CD52 and CD20 levels predict for progression and survival in patients with CLL treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR). American Society of Hematology (ASH) annual meeting. Blood 108(11) (#2330), 2006.
15. Alatrash G, Hutson TE, Nemec C, Mekhail T, Richmond A, Molto L, Elson P, Tannenbaum C, Finke J, Olencki T, Bukowski RM. Toxicity and immunologic effects of subcutaneously (SC) administered IL-12 and IFN-a2b in patients (Pts) with metastatic renal cell carcinoma (RCC) or malignant melanoma (MM). American Society of Clinical Oncology (ASCO) annual meeting. Journal of Clinical Oncology (#705), 2003.
16. Alatrash G, Kitson RP, Kim MH, Mazar AP, Goldfarb RH. Urokinase plasminogen activator and its receptor in NK cells: Contribution to extacelluar matrix degradation and impact on NK cell accumulation into cancer metastases. Federation of American Societies for Experimental Biology (FASEB) 14(6):A1024, 4/2000.

Book Chapters

1. Alatrash G, Molldrem JJ. Tumor-associated antigens. In: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation Models in Discovery and Translation. Ed(s) Socie G, Blazar B. Elsevier, 143-159, 2013. ISBN: 978-0-12-374718-1.
2. Alatrash G, de Lima M. Stem Cell Transplant for AML. In: Leukemias: Principles and Practice of Therapy. Ed(s) Faderl S, Kantarjian H. Blackwell Publishing, 2008.
3. Alatrash G, Bukowski R, Tannenbaum C, Finke J. Interleukins. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams and Wilkins, 2006.

Grant & Contract Support

Title: Myeloma SPORE: Cross-presented Antigens as Novel Targets in Multiple Myeloma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2015 - 12/31/2015
 
Title: Investigation of ex vivo fucosylation to enhance the efficacy of adoptive T cell immunotherapy
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2014 - 9/30/2017
 
Title: Project 4: Novel Detection Algorithms and Stem Cell-Targeting Treatments
Funding Source: MD Anderson Moonshot Program
Role: Co-Principal Investigator
Principal Investigator: Robert Orlowski
Duration: 9/1/2014 - 8/31/2018
 
Title: Cathepsin G Is A Novel Myeloid Leukemia Target
Funding Source: Leukemia Research Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 12/31/2013
 
Title: Leukemia SPORE: Cathepsin G in Anti-leukemia Immunity
Funding Source: NIH/NCI
Role: Project Leader
Duration: 5/1/2012 - 4/30/2014
 
Title: Anti-PR1/HLA-A2 Immunity in Myeloid Leukemia
Funding Source: Gabrielle's Angel Foundation
Role: Principal Investigator
Duration: 10/1/2011 - 12/31/2014
 
Title: Cyclin E: A Novel Target for Immunotherapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Elizabeth Mittendorf
Duration: 10/1/2011 - 8/31/2013
 
Title: Breast SPORE: Development of Antibody-Targeted Peptide Vaccines as Novel Components of Combination Immunotherapy
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Elizabeth Mittendorf
Duration: 10/1/2011 - 8/31/2012
 
Title: Breast SPORE: Role of Cross Presentation in PR1 Immunity Against Breast Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2011 - 8/31/2012
 
Title: Cross Presentation in Anti-leukemia Immunity
Funding Source: NIH/NCI (LRP)
Role: Principal Investigator
Duration: 7/1/2010 - 9/1/2014
 
Title: Anti-leukemia Immunity and Vaccine Development
Funding Source: University of Texas MD Anderson Cancer Center Research Start-up funds
Role: Principal Investigator
Duration: 3/1/2010 - 3/1/2015
 
Title: Anti-leukemia Immunity Following PR1 Vaccine Therapy
Funding Source: American Society of Clinical Oncology (ASCO), Young Investigator Award (YIA)
Role: Principal Investigator
Duration: 11/1/2007 - 11/1/2008
 
Title: Anti-leukemia Immunity Following PR1 Vaccine Therapy
Funding Source: NIH/NCI (LRP)
Role: Mentored Fellow
Duration: 2007 - 2009

Last updated: 8/18/2015